Dr. Rugo on Rationale for the ELAINE Study in ESR1-Mutated ER+|HER2- Breast Cancer

Hope S. Rugo, MD, a professor in the Department of Medicine and director of Breast Oncology and Clinical Trials Education at University of California, San Francisco, discusses the rationale for the ELAINE study in breast cancer.

Website:
Twitter:
Facebook:
LinkedIn:

cancer,oncology,ELAINE study,breast cancer,lasofoxifene,fulvestrant,